Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proceedings of the National Academy of Sciences of the United States of America Sagiv-Barfi, I., Kohrt, H. E., Czerwinski, D. K., Ng, P. P., Chang, B. Y., Levy, R. 2015; 112 (9): E966-72
View details for DOI 10.1073/pnas.1500712112
View details for PubMedID 25730880